VFEND is a Intravenous Injection, Powder, Lyophilized, For Solution in the Human Prescription Drug category. It is labeled and distributed by Roerig. The primary component is Voriconazole.
| Product ID | 0049-4190_4be3e0d5-6bae-4ebb-8691-cec3d1781ec9 |
| NDC | 0049-4190 |
| Product Type | Human Prescription Drug |
| Proprietary Name | VFEND |
| Generic Name | Voriconazole |
| Dosage Form | Injection, Powder, Lyophilized, For Solution |
| Route of Administration | INTRAVENOUS |
| Marketing Start Date | 2012-10-24 |
| Marketing Category | NDA / NDA |
| Application Number | NDA021267 |
| Labeler Name | Roerig |
| Substance Name | VORICONAZOLE |
| Active Ingredient Strength | 10 mg/mL |
| Pharm Classes | Azole Antifungal [EPC], Azoles [CS], Cytochrome P450 2C19 Inhibitors [MoA], Cytochrome P450 2C9 Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2023-12-31 |
| Marketing Start Date | 2012-10-24 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | NDA |
| Application Number | NDA021267 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | EA |
| Marketing Start Date | 2012-10-24 |
| Ingredient | Strength |
|---|---|
| VORICONAZOLE | 10 mg/mL |
| SPL SET ID: | 08d08721-1f4c-478a-8abf-d9c402d50553 |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 0049-3160 | VFEND | voriconazole |
| 0049-3170 | VFEND | voriconazole |
| 0049-3180 | VFEND | voriconazole |
| 0049-3190 | VFEND | voriconazole |
| 55154-2725 | VFEND | VFEND |
| 0049-4190 | VFEND | VFEND |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() VFEND 78469910 3017665 Live/Registered |
PFIZER IRELAND PHARMACEUTICALS 2004-08-19 |
![]() VFEND 76269065 not registered Dead/Abandoned |
Pfizer Inc. 2001-06-07 |
![]() VFEND 75122046 2455588 Live/Registered |
PFIZER IRELAND PHARMACEUTICALS 1996-06-19 |